155 related articles for article (PubMed ID: 16279022)
1. [Sevelamer hydrochloride and K/DOQI guidelines].
Yumita S
Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
[No Abstract] [Full Text] [Related]
2. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
Hoshino J; Ubara Y; Takaichi K
Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
[TBL] [Abstract][Full Text] [Related]
4. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
5. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
[No Abstract] [Full Text] [Related]
6. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
7. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
Ferreira A; Frazão JM; Monier-Faugere MC; Gil C; Galvao J; Oliveira C; Baldaia J; Rodrigues I; Santos C; Ribeiro S; Hoenger RM; Duggal A; Malluche HH;
J Am Soc Nephrol; 2008 Feb; 19(2):405-12. PubMed ID: 18199805
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].
Tahara H; Tsujimoto Y; Shouji T; Inaba M; Tabata T; Nishizawa Y
Clin Calcium; 2005 Sep; 15 Suppl 1():173-9. PubMed ID: 16279021
[No Abstract] [Full Text] [Related]
9. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
10. [Control of calcium and phosphate in hemodialysis patients].
Eriguchi R; Takei S; Satou Y
Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
[TBL] [Abstract][Full Text] [Related]
11. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
12. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.
Wesseling-Perry K; Harkins GC; Wang HJ; Sahney S; Gales B; Elashoff RM; Jüppner H; Salusky IB
Pediatr Nephrol; 2009 Jul; 24(7):1355-61. PubMed ID: 19301038
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
14. [Management of secondary hyperparathyroidism].
Cunningham J
Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
[No Abstract] [Full Text] [Related]
15. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
[TBL] [Abstract][Full Text] [Related]
16. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
17. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
[TBL] [Abstract][Full Text] [Related]
18. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
19. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
[TBL] [Abstract][Full Text] [Related]
20. Fluoride and dialysis osteodystrophy: results of a double-blind study.
Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
